Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects

BACKGROUND AND OBJECTIVES: Dalbavancin is a novel, once-weekly glycopeptide antibiotic approved for treatment of acute bacterial skin infections. Given the importance of understanding any pharmacokinetic variability across different patient populations, a double-blind, placebo-controlled study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Scoble, Patrick J., Owens, Robert C., Puttagunta, Sailaja, Yen, Mark, Dunne, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659844/
https://www.ncbi.nlm.nih.gov/pubmed/26458939
http://dx.doi.org/10.1007/s40261-015-0340-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659844/
https://www.ncbi.nlm.nih.gov/pubmed/26458939
http://dx.doi.org/10.1007/s40261-015-0340-4

Ejemplares similares